omeprazole and erlotinib hydrochloride

omeprazole has been researched along with erlotinib hydrochloride in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Bradbury, PA; Hilton, JF; Seymour, L; Shepherd, FA; Tu, D1
Basappa, N; Butts, CA; Chambers, CR; Chu, MP; Chu, Q; Fenton, D; Ghosh, S; Joy, AA; Sangha, R; Sawyer, MB; Smylie, M1
Lin, C; Lin, G; Ma, J; Wang, S; Wang, X; Zhang, M; Zhang, Q; Zhou, Y1
Abt, M; Ducray, PS; Giraudon, M; Hamilton, M; Kletzl, H; Lum, BL1
Nagase, K; Ogawa, Y; Okano, M; Sai, Y; Shimada, T; Ueda, A; Yamada, M1

Trials

1 trial(s) available for omeprazole and erlotinib hydrochloride

ArticleYear
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
    Anti-cancer drugs, 2015, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Ranitidine; Young Adult

2015

Other Studies

4 other study(ies) available for omeprazole and erlotinib hydrochloride

ArticleYear
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:1

    Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Ranitidine; Retrospective Studies; Stomach Ulcer; Treatment Outcome

2013
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
    Clinical lung cancer, 2015, Volume: 16, Issue:1

    Topics: Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Omeprazole; Population Groups; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome

2015
Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats.
    Biomedical chromatography : BMC, 2015, Volume: 29, Issue:8

    Topics: Adjuvants, Anesthesia; Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Erlotinib Hydrochloride; Hypoglycemic Agents; Limit of Detection; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenacetin; Protein Kinase Inhibitors; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tolbutamide

2015
Administration of erlotinib in apple juice overcomes decreased absorption in a rat model of gastric acid suppression.
    Drug metabolism and pharmacokinetics, 2020, Volume: 35, Issue:6

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Erlotinib Hydrochloride; Food-Drug Interactions; Fruit and Vegetable Juices; Gastric Acid; Gastric Mucosa; Gastrointestinal Absorption; Hydrogen-Ion Concentration; Male; Malus; Omeprazole; Proton Pump Inhibitors; Rats, Wistar; Solubility

2020